Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Viral load and the duration of viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are important determinants of the transmission of coronavirus disease 2019.In this study, we examined the effects of viral doses on the lung and spleen of K18-hACE2 transgenic mice by temporal histological and transcriptional analyses. Approximately, 1×105 plaque-forming units (PFU) of SARS-CoV-2 induced strong host responses in the lungs from 2 days post inoculation (dpi) which did not recover until the mice died, whereas responses to the virus were obvious at 5 days, recovering to the basal state by 14 dpi at 1×102 PFU. Further, flow cytometry showed that number of CD8+ T cells continuously increased in 1×102 PFU-virusinfected lungs from 2 dpi, but not in 1×105 PFU-virus-infected lungs. In spleens, responses to the virus were prominent from 2 dpi, and number of B cells was significantly decreased at 1×105PFU; however, 1×102 PFU of virus induced very weak responses from 2 dpi which recovered by 10 dpi. Although the defense responses returned to normal and the mice survived, lung histology showed evidence of fibrosis, suggesting sequelae of SARS-CoV-2 infection. Our findings indicate that specific effectors of the immune response in the lung and spleen were either increased or depleted in response to doses of SARS-CoV-2. This study demonstrated that the response of local and systemic immune effectors to a viral infection varies with viral dose, which either exacerbates the severity of the infection or accelerates its elimination.

In the 2023–2024 season, the influenza epidemic in South Korea peaked earlier than in recent years. In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, −51.3 to 45.7) for influenza A/H1N1. Full results of the analysis will be reported.

Background: Bivalent booster mRNA vaccines containing the omicron-variant strains have been introduced worldwide in the autumn of 2022. Nevertheless, the omicron subvariants evoked another large coronavirus disease 2019 (COVID-19) pandemic wave in late 2022 and early 2023. Methods: A retrospective, test-negative, case-control study was conducted to estimate the vaccine effectiveness (VE) of bivalent COVID-19 vaccines in 8 university hospitals between January and February 2023. The case and control groups were divided based on nasopharyngeal COVID-19 real-time polymerase chain reaction results and matched based on age, sex, hospital, and date (week) of the test performed. The VE of the BA.1- or BA.4/BA.5-based mRNA vaccines were estimated. VE was calculated using the 1−adjusted odds ratio from multivariable logistic regression. Results: In total, 949 patients and 947 controls were enrolled in this study. VE for the BA.4/ BA.5-based bivalent mRNA vaccine was 43% (95% confidence interval [CI], 17, 61%). In subgroup analysis based on age and underlying medical conditions, BA.4/BA.5-based bivalent mRNA vaccine was effective against old adults aged ≥ 65-years (VE, 55%; 95% CI, 23, 73%) and individuals with comorbidities (VE, 54%; 95% CI, 23, 73%). In comparison, the BA.1-based bivalent mRNA vaccine did not demonstrate statistically significant effectiveness (VE, 25%; 95% CI, −8, 49%). Conclusion The BA.4/BA.5-based bivalent mRNA booster vaccine provided significant protection against COVID-19 in the Korean adults, especially in the older adults aged ≥ 65 years and in individuals with underlying medical conditions.

Objective: To compare transverse and longitudinal safe zones using ultrasonography between healthy individuals and patients with carpal tunnel syndrome (CTS). Methods: This was a prospective observational case-control study. Forty wrists from 20 healthy individuals and 40 wrists from 24 patients with CTS were examined. Patients with CTS were classified into three groups (mild, moderate, and severe CTS) based on electrodiagnostic findings. Using ultrasonography, we measured the distance between the median nerve and ulnar vessels to identify the transverse safe zone, and between the distal flexor retinaculum and superficial palmar artery arch to identify the longitudinal safe zone. Results: The transverse and longitudinal safe zones were significantly different between participants with CTS and those without CTS. The transverse safe zone significantly differed between the mild and severe CTS groups, while the longitudinal safe zone was not significantly different between the groups. The cross-sectional area of the median nerve negatively correlated with the transverse and longitudinal safe zones. Conclusion Transverse and longitudinal safe zones were narrower in patients with CTS than in the healthy group. A significant difference was observed between patients with mild CTS and those with severe CTS. Furthermore, the cross-sectional area of the median nerve was directly proportional to the degree of narrowing of the transverse and longitudinal safe zones.

Purpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods: In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3–4, 5–6, and 7–8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression.